Abstract | BACKGROUND AND PURPOSE: METHODS: Oral deferiprone, a lipid-soluble iron chelator with ability to cross the blood-brain barrier, at a dose of 30 mg/kg per day was tested for safety in an open pilot study in 10 subjects with superficial siderosis. RESULTS: Over a 90-day period, deferiprone had no significant adverse effects on hematologic, liver, or neurological function. Ad hoc MRI assessments of the brain indicated a reduction in hemosiderin deposition in some subjects. CONCLUSIONS:
|
Authors | Michael Levy, Rafael Llinas |
Journal | Stroke
(Stroke)
Vol. 43
Issue 1
Pg. 120-4
(Jan 2012)
ISSN: 1524-4628 [Electronic] United States |
PMID | 22034002
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Pyridones
- Deferiprone
- Hemosiderin
|
Topics |
- Adult
- Aged
- Brain
(drug effects, metabolism)
- Deferiprone
- Female
- Hemosiderin
(metabolism)
- Humans
- Male
- Middle Aged
- Pilot Projects
- Pyridones
(adverse effects, therapeutic use)
- Siderosis
(drug therapy, metabolism)
- Treatment Outcome
|